Teva Pharmaceutical Industries said that the phase IIIb FOCUS study that evaluated the efficacy and safety of fremanezumab for the preventive treatment of migraine in adult patients has yielded positive results.
Vedanta Biosciences, which was founded by PureTech Health, has commenced a phase 2 study of its rationally-defined bacterial consortium product candidate, VE303, for recurrent Clostridium difficile infection (rCDI).
Janssen Pharmaceutical said that Tremfya (guselkumab) was found to be superior to Cosentyx (secukinumab) for the primary endpoint assessed at week 48 of a phase 3 trial in adults with moderate to severe plaque psoriasis.
Ra Pharmaceuticals’ (Ra Pharma) zilucoplan has succeeded in a phase 2 trial in generalized myasthenia gravis (gMG) by meeting the primary and key secondary end points.
Bristol-Myers Squibb will evaluate Opdivo (nivolumab) in combination with Vedanta Biosciences’ VE800, a live biotherapeutic product (LBP), in patients with advanced or metastatic cancers.
Eisai said that the first investigational drug candidate from its drug discovery collaboration with University College London (UCL) is set to enter Phase I clinical trials for Alzheimer's disease (AD) in early 2019.
AstraZeneca said that the combination of its Imfinzi (durvalumab) monotherapy and tremelimumab has failed to improve overall survival (OS) rate compared to standard-of-care (SoC) chemotherapy in a head and neck cancer trial.
Novartis has initiated phase III trials for its monoclonal anti-IgE antibody ligelizumab (QGE031) in chronic spontaneous urticaria (CSU) patients whose symptoms are inadequately controlled by H1-antihistamines.
Data analytics company Ixico has signed an expanded scope to an existing contract with a top 10 biopharmaceutical company.
Johnson & Johnson’s (J&J) Darzalex (daratumumab), in combination with lenalidomide and dexamethasone (Rd), has significantly reduced the risk of disease progression in multiple myeloma study.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.